Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRN030
MIFTS: 52

Coronary Stenosis

Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Coronary Stenosis

About this section

MalaCards integrated aliases for Coronary Stenosis:

Name: Coronary Stenosis 12 51 41 14 69
Coronary Artery Stenosis 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4248
MeSH 41 D023921
NCIt 46 C80427
SNOMED-CT 64 233970002
UMLS 69 C0242231
Sources

Summaries for Coronary Stenosis

About this section
MalaCards based summary : Coronary Stenosis, also known as coronary artery stenosis, is related to kawasaki disease and acute myocardial infarction, and has symptoms including angina pectoris An important gene associated with Coronary Stenosis is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Lipoprotein metabolism. The drugs Aspirin and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are Decreased free cholesterol and cardiovascular system

Sources

Related Diseases for Coronary Stenosis

About this section

Diseases related to Coronary Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 kawasaki disease 30.3 ALB CRP IL6
2 acute myocardial infarction 29.8 ACE CRP SERPINE1 TNNI3 VWF
3 angina pectoris 29.8 ACE CRP IL6 SERPINE1 VWF
4 aortic aneurysm, familial abdominal, 1 29.6 ACE APOE CRP IL6
5 myocarditis 29.4 ICAM1 IL6 TNNI3
6 chlamydia 29.3 CRP IL6 TLR4
7 aortic valve disease 2 29.3 ACE CRP TNNI3 VWF
8 pneumonia 29.1 CRP IL6 TLR4
9 diabetes mellitus 29.1 ACE ALB CRP IL6 PON1
10 crohn's disease 29.1 CRP IL6 TLR4
11 ischemic heart disease 29.0 ACE APOA1 APOB APOE CRP IL6
12 coronary artery anomaly 28.4 ACE APOA1 APOB APOE CETP CRP
13 body mass index quantitative trait locus 11 28.1 APOA1 APOB APOE CETP CRP IL6
14 hypercholesterolemia, familial 28.1 APOA1 APOB APOE CETP CRP PCSK9
15 heart disease 27.7 ACE ALB APOB APOE CRP IL6
16 coronary heart disease 1 27.4 ACE APOA1 APOB APOE CETP CRP
17 arteries, anomalies of 26.8 ACE ALB APOA1 APOB APOE CETP
18 myocardial infarction 26.0 ACE ALB APOA1 APOB APOE CETP
19 cold agglutinin disease 10.5 CRP IL6
20 moderate and severe traumatic brain injury 10.5 ACE APOE
21 diabetic foot ulcers 10.5 CRP IL6
22 cryopyrin-associated periodic syndrome 10.5 CRP IL6
23 neutrophilia, hereditary 10.5 CRP IL6
24 acute cholangitis 10.5 CRP IL6
25 cardiogenic shock 10.5 CRP IL6
26 acute transverse myelitis 10.4 APOA1 IL6
27 uremic pruritus 10.4 CRP IL6
28 hepatic lipase deficiency 10.4 APOA1 APOE
29 generalized atherosclerosis 10.4 ACE APOE CRP
30 systolic heart failure 10.4 ACE CRP IL6
31 spinal disease 10.3 CRP IL6
32 xanthoma disseminatum 10.3 APOB APOE
33 blue toe syndrome 10.3 CRP SERPINE1
34 pyuria 10.3 ALB CRP
35 cerebral atherosclerosis 10.3 ACE APOA1 APOE
36 hypercholesterolemia, autosomal dominant, type b 10.3 APOB APOE
37 acute cystitis 10.3 ALB CRP IL6
38 orthostatic proteinuria 10.3 ACE ALB
39 acute pyelonephritis 10.3 ALB CRP IL6
40 hemorrhagic fever with renal syndrome 10.3 ALB CRP IL6
41 defective apolipoprotein b-100 10.3 APOB APOE
42 dirofilariasis 10.3 CRP PON1 TNNI3
43 appendicitis 10.3 ALB CRP IL6
44 hypertensive retinopathy 10.3 ACE VWF
45 castleman disease 10.3 CRP IL6
46 familial lcat deficiency 10.3 ALB APOA1 APOE
47 bacterial meningitis 10.3 ALB CRP IL6
48 gastroenteritis 10.3 ALB CRP IL6
49 vascular dementia 10.3 ACE APOE PON1
50 coronary restenosis 10.3 ACE CETP

Graphical network of the top 20 diseases related to Coronary Stenosis:



Diseases related to Coronary Stenosis
Sources

Symptoms & Phenotypes for Coronary Stenosis

About this section

UMLS symptoms related to Coronary Stenosis:


angina pectoris

GenomeRNAi Phenotypes related to Coronary Stenosis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.02 APOA1 APOB APOE CETP PCSK9

MGI Mouse Phenotypes related to Coronary Stenosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 PON1 SERPINE1 APOE TLR4 CRP ACE
2 homeostasis/metabolism MP:0005376 10.13 APOB PON1 SERPINE1 APOE TLR4 CRP
3 cellular MP:0005384 10.02 PON1 APOB APOE ICAM1 ALB IL6
4 immune system MP:0005387 9.91 APOB SERPINE1 APOE CRP ACE ICAM1
5 liver/biliary system MP:0005370 9.81 APOB SERPINE1 APOE TLR4 ACE ALB
6 muscle MP:0005369 9.5 APOB APOE TLR4 ICAM1 ALB IL6
7 neoplasm MP:0002006 9.1 SERPINE1 ACE ICAM1 ALB IL6 TLR4
Sources

Drugs & Therapeutics for Coronary Stenosis

About this section

Drugs for Coronary Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
2
Clopidogrel Approved Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
3
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
5
Cilostazol Approved, Investigational Phase 4,Phase 3 73963-72-1 2754
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
7
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
8
Azathioprine Approved Phase 4 446-86-6 2265
9
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
10
Mycophenolic acid Approved Phase 4 24280-93-1 446541
11
Chromium Approved Phase 4,Phase 2,Phase 3 7440-47-3 27668
12
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
13
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
14
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2 58-61-7 60961
15
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
16
Regadenoson Approved, Investigational Phase 4,Phase 2 313348-27-5 219024
17
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
18
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
19
Nitric Oxide Approved Phase 4 10102-43-9 145068
20
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 55-56-1 2713 9552079
21
Iodine Approved, Investigational Phase 4 7553-56-2 807
22
Ticagrelor Approved Phase 4 274693-27-5 9871419
23
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 1
24
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
25
Probucol Approved, Investigational Phase 4 23288-49-5 4912
26
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
27
Dobutamine Approved Phase 4,Phase 3 34368-04-2 36811
28
Liraglutide Approved Phase 4 204656-20-2 44147092
29
Glucosamine Approved, Investigational, Nutraceutical Phase 4,Phase 2 3416-24-8 439213
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
31 Orange Approved, Nutraceutical Phase 4
32
Sarpogrelate Investigational Phase 4 125926-17-2 5160
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Anti-Asthmatic Agents Phase 4,Phase 3
35 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
37 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Autonomic Agents Phase 4,Phase 3
40 Bronchodilator Agents Phase 4,Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
42 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Neuroprotective Agents Phase 4,Phase 3
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
45 Peripheral Nervous System Agents Phase 4,Phase 3
46 Phosphodiesterase 3 Inhibitors Phase 4,Phase 3
47 Phosphodiesterase Inhibitors Phase 4,Phase 3
48 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
49 Protective Agents Phase 4,Phase 3
50 Purinergic P2 Receptor Antagonists Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 417)

# Name Status NCT ID Phase Drugs
1 Fractional Flow Reserve and Intravascular Ultrasound in Evaluating Intermediate Coronary Lesions Unknown status NCT01414361 Phase 4
2 Comparison of Fractional Flow Reserve and Intravascular Ultrasound Unknown status NCT01133015 Phase 4
3 Monitoring Response to Antiplatelet Therapy Unknown status NCT00327041 Phase 4
4 Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Unknown status NCT01342822 Phase 4
5 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
6 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
7 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
8 Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant Unknown status NCT00695344 Phase 4 everolimus;azathioprine or mycophenolate mofetil
9 COMPETE: A Clinical Evaluation of Chrono Carbostent Carbofilm™ Coated Stent Unknown status NCT00920283 Phase 4
10 Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions Unknown status NCT01278186 Phase 4
11 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
12 SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents Unknown status NCT00714545 Phase 4
13 A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis Completed NCT01513070 Phase 4 Quick-Acting Heart Reliever;Isosorbide Dinitrate;Placebo of Isosorbide Dinitrate;Aspirin Enteric-coated Tablets;Placebo of Quick-Acting Heart Reliever;Aspirin Enteric-coated Tablets
14 Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With Magnetic Resonance Imaging (MRI) Completed NCT00188123 Phase 4
15 The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.) Completed NCT00403338 Phase 4
16 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
17 Excel Drug-Eluting Stent Pilot Clinical Registry Completed NCT00385905 Phase 4
18 Contrast Enhancement on Coronary Computed Tomographic Angiography Completed NCT02462044 Phase 4 240 mg Iodine;300 mg Iodine;370 mg Iodine
19 Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Completed NCT02120859 Phase 4
20 Kidney Damage in Patients With Normal eGFR Completed NCT01137786 Phase 4 Non ionic contrast media comparator;Non ionic contrast media comparator
21 Kidney Damage in Patients With Moderate Fall in eGFR Completed NCT01136876 Phase 4 Iopamidol;Iodixanol-320
22 Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT01200693 Phase 4
23 SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT00697372 Phase 4
24 Vision II: Evaluation of GALILEO Intravascular Radiotherapy System Completed NCT00180583 Phase 4
25 The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers Completed NCT00494559 Phase 4 Pioglitazone;Placebo
26 Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance Completed NCT01582165 Phase 4 Rosuvastatin;Placebo.
27 Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth Completed NCT00349895 Phase 4
28 Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents Completed NCT00627900 Phase 4
29 Comparison of Zotarolimus-Eluting Stent vs Sirolimus-Eluting Stent for Diabetic Patients Completed NCT01186107 Phase 4
30 Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus Completed NCT00997763 Phase 4
31 Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions Completed NCT00418067 Phase 4
32 Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study) Completed NCT00375063 Phase 4
33 EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease Completed NCT01310309 Phase 4
34 EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Completed NCT00531011 Phase 4
35 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Completed NCT01255722 Phase 4 iobitridol;iopromide;iomeprol
36 Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents Completed NCT01056744 Phase 4
37 Sirolimus-Eluting Stent Versus Standard Stent in Diabetic Completed NCT00755443 Phase 4
38 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson Completed NCT01779869 Phase 4 Regadenoson
39 Effect of Ticagrelor on Fractional Flow Reserve Completed NCT02108808 Phase 4 Ticagrelor;Prasugrel or Clopidogrel
40 Austrian Multivessel Taxus-Stent Registry Completed NCT00738686 Phase 4
41 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente Completed NCT01066650 Phase 4
42 Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
43 QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia Completed NCT00150826 Phase 4 Quinapril;Placebo
44 Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement Completed NCT01070420 Phase 4
45 Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
46 Aspirin Twice Daily in Diabetic Patients With Coronary Artery Disease Completed NCT01617031 Phase 4
47 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population Completed NCT01331707 Phase 4
48 Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
49 XIENCE V: SPIRIT WOMEN Sub-study Completed NCT01182428 Phase 4
50 XIENCE V: SPIRIT WOMEN Completed NCT00496938 Phase 4

Search NIH Clinical Center for Coronary Stenosis

Cochrane evidence based reviews: coronary stenosis

Sources

Genetic Tests for Coronary Stenosis

About this section
Sources

Anatomical Context for Coronary Stenosis

About this section

MalaCards organs/tissues related to Coronary Stenosis:

38
Heart, Testes, Endothelial, Kidney, Liver, Monocytes, Brain
Sources

Publications for Coronary Stenosis

About this section

Articles related to Coronary Stenosis:

(show top 50) (show all 617)
# Title Authors Year
1
The characteristics of coronary stenosis in 11,267 patients from Southwest China: a retrospective study. ( 29019045 )
2018
2
Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. ( 29308090 )
2018
3
Resting Pd/Pa and haemodynamic relevance of coronary stenosis as evaluated by fractional flow reserve. ( 29028737 )
2018
4
Combined Assessment of Stress Myocardial Perfusion Cardiovascular Magnetic Resonance and Flow Measurement in the Coronary Sinus Improves Prediction of Functionally Significant Coronary Stenosis Determined by Fractional Flow Reserve in Multivessel Disease. ( 29432130 )
2018
5
Calcification remodeling index assessed by cardiac CT predicts severe coronary stenosis in lesions with moderate to severe calcification. ( 28988831 )
2018
6
Diagnostic Concordance and Clinical Outcomes in Patients Undergoing Fractional Flow Reserve and Stress Echocardiography for the Assessment of Coronary Stenosis of Intermediate Severity. ( 29246509 )
2018
7
Intermediate CD14(++)CD16(+) monocyte predicts severe coronary stenosis and extensive plaque involvement in asymptomatic individuals. ( 28239800 )
2017
8
Efficacy of Optical Coherence Tomography-derived Morphometric Assessment in Predicting the Physiological Significance of Coronary Stenosis: Head-to-Head Comparison with Intravascular Ultrasound. ( 29155383 )
2017
9
Intravascular Images of Coronary Stenosis with Multiple Channels in a Patient with Antiphospholipid Syndrome: The Optical Coherence Tomography Findings. ( 28566597 )
2017
10
Electronic Stethoscope for Coronary Stenosis Detection. ( 28431676 )
2017
11
Correction to: Assessing Computational Fractional Flow Reserve From Optical Coherence Tomography in Patients With Intermediate Coronary Stenosis in the Left Anterior Descending Artery. ( 28062519 )
2017
12
Applicability of 3-Dimensional Quantitative Coronary Angiography-Derived Computed Fractional Flow Reserve for Intermediate Coronary Stenosis. ( 28331135 )
2017
13
Outcomes of Coronary Artery Bypass and Stents for Unprotected Left Main Coronary Stenosis. ( 28223049 )
2017
14
Left main coronary stenosis: surgery still reigns. ( 28797009 )
2017
15
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). ( 28794001 )
2017
16
Bioresorbable Scaffolds for Coronary Stenosis: When and How Based Upon Current Studies. ( 28299676 )
2017
17
Sestrins increase in patients with coronary artery disease and associate with the severity of coronary stenosis. ( 28732653 )
2017
18
Coronary Stenosis after Kawasaki Disease: Size Matters. ( 29248184 )
2017
19
Propensity-Score Matched Comparison of Midterm Angiographic Outcomes of Sirolimus- Versus Everolimus- and Biolimus-Eluting Stents for De Novo Coronary Stenosis. ( 28484124 )
2017
20
Three-year follow-up of patients with acetylcholine-induced coronary artery spasm combined with insignificant coronary stenosis. ( 28457560 )
2017
21
An investigation of correlation between left coronary bifurcation angle and hemodynamic changes in coronary stenosis by coronary computed tomography angiography-derived computational fluid dynamics. ( 29184766 )
2017
22
Influence of increased heart rate and aortic pressure on resting indices of functional coronary stenosis severity. ( 28905113 )
2017
23
Effect modification of hypertension on the association of vitamin D deficiency with severity of coronary stenosis. ( 29254371 )
2017
24
What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis? ( 28903135 )
2017
25
Quantification of left coronary bifurcation angles and plaques by coronary computed tomography angiography for prediction of significant coronary stenosis: A preliminary study with dual-source CT. ( 28346530 )
2017
26
Diagnostic Accuracy of Angiography-Based Quantitative FlowA Ratio Measurements for Online AssessmentA of Coronary Stenosis. ( 29101020 )
2017
27
Young Athlete With Complex Aneurysmal Coronary Stenosis. ( 29207369 )
2017
28
Influence of the amount of myocardium subtended to a coronary stenosis on the index of microcirculatory resistance. Implications for the invasive assessment of microcirculatory function in ischemic heart disease. ( 28485281 )
2017
29
Difference of coronary stenosis severity between systolic and diastolic phases in quantitative CT angiography. ( 28126251 )
2017
30
Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old. ( 29113395 )
2017
31
Stenotic flow reserve derived from quantitative coronary angiography has modest but incremental value in predicting functionally significant coronary stenosis as evaluated by fractional flow reserve. ( 28164013 )
2017
32
Chronic Periaortitis of Ascending Aorta With Bilateral Ostial Coronary Stenosis in a Young Female. ( 28431717 )
2017
33
Clues to Discordance and Dissimilarity Between Coronary Stenosis and Lesion-Specific Ischemia. ( 28687541 )
2017
34
Noninvasive measurement of pressure gradient across a coronary stenosis using phase contrast (PC)-MRI: A feasibility study. ( 28019028 )
2017
35
Fractional Flow Reserve Assessment of a Significant Coronary Stenosis Masked by a Downstream Serial Lesion. ( 27529035 )
2016
36
The coronary calcium score is a more accurate predictor of significant coronary stenosis than conventional risk factors in symptomatic patients: Euro-CCAD study. ( 26784565 )
2016
37
Coronary Flow Reserve and Microcirculatory Resistance in Patients With Intermediate Coronary Stenosis. ( 26965536 )
2016
38
First-In-Man 6-month results of Qvanteq Surface-modified Coronary Stent System in Native Coronary Stenosis. ( 27993758 )
2016
39
Relationship between hsTnI and coronary stenosis in asymptomatic women with rheumatoid arthritis. ( 27686126 )
2016
40
Simultaneous rota-stenting and transcatheter aortic valve implantation for patients with heavily calcified coronary stenosis and aortic stenosis. ( 27344931 )
2016
41
Troponin I Assay for Identification of a Significant Coronary Stenosis in Patients with Suspected Acute Myocardial Infarction and Wide QRS Complex. ( 27148734 )
2016
42
Strain Imaging with a Bull's-Eye Map for Detecting Significant Coronary Stenosis during Dobutamine Stress Echocardiography. ( 27916236 )
2016
43
Copeptin and high-sensitivity cardiac troponin to exclude severe coronary stenosis in patients with chest pain and coronary artery disease. ( 26851061 )
2016
44
Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity: The VERIFY 2 Study (A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-Free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography). ( 27834663 )
2016
45
Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis. ( 27829581 )
2016
46
A Preoperative Assessment of Significant Coronary Stenosis Based on a Semiquantitative Analysis of Coronary Artery Calcification on Noncontrast Computed Tomography in Aortic Stenosis Patients Undergoing Aortic Valve Replacement. ( 26945385 )
2016
47
Reactive Myocardial Hyperemia for Functional Assessment of Coronary Stenosis Severity. ( 27993753 )
2016
48
TCT-504 Comparison of Computed Tomography derived Fractional Flow Reserve to invasive Fractional Flow Reserve in Diagnosis of Functional Coronary Stenosis: A Meta-Analysis. ( 27969867 )
2016
49
Modification of the association between smoking status and severity of coronary stenosis by vitamin D in patients suspected of coronary heart disease. ( 27603397 )
2016
50
Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI. ( 27034431 )
2016
Sources

Variations for Coronary Stenosis

About this section
Sources

Expression for Coronary Stenosis

About this section
Search GEO for disease gene expression data for Coronary Stenosis.
Sources

Pathways for Coronary Stenosis

About this section

Pathways related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Toll-like receptor signaling pathway 1 36
Show member pathways
 12.34 ACE IL6 SERPINE1 TLR4
2
Lipoprotein metabolism 62
Show member pathways
 12.17 ALB APOA1 APOB APOE CETP PCSK9
3
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.88 ALB IL6 TNNI3
4
p53 Pathway (RnD) 61
11.87 ICAM1 SERPINE1 TLR4
5
Spinal Cord Injury 1
11.81 ICAM1 IL6 TLR4
6
Ca, cAMP and Lipid Signaling 4
11.73 ALB APOA1 APOE TNNI3
7
HIF-1 signaling pathway 36
11.71 IL6 SERPINE1 TLR4
8
AGE-RAGE signaling pathway in diabetic complications 36
11.7 ICAM1 IL6 SERPINE1
9
Cytokine production by Th17 cells in CF (Mouse model) 21
Show member pathways
 11.65 ICAM1 IL6 TLR4
10
Rheumatoid arthritis 36
11.63 ICAM1 IL6 TLR4
11
Binding and Uptake of Ligands by Scavenger Receptors 62
Show member pathways
 11.57 ALB APOA1 APOB APOE
12
Selenium Micronutrient Network 1
Show member pathways
 11.56 ALB APOA1 APOB APOE CRP ICAM1
13
IgA-Producing B Cells in the Intestine 61
11.47 ICAM1 IL6 TLR4
14
Statin Pathway 1
Show member pathways
 11.43 APOA1 APOB APOE CETP PCSK9
15
Malaria 36
11.32 ICAM1 IL6 TLR4
16
amb2 Integrin signaling 1
11.29 APOB ICAM1 IL6
17
African trypanosomiasis 36
11.12 APOA1 ICAM1 IL6
18
A-beta Pathways: Uptake and Degradation 61
11.05 ACE APOE TLR4
19
Overview of nanoparticle effects 1
10.85 CRP IL6
Sources

GO Terms for Coronary Stenosis

About this section

Cellular components related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.91 APOA1 APOE ICAM1 SERPINE1 VWF
2 early endosome GO:0005769 9.86 APOA1 APOB APOE PCSK9
3 blood microparticle GO:0072562 9.83 ALB APOA1 APOE PON1
4 endoplasmic reticulum lumen GO:0005788 9.8 ALB APOA1 APOB APOE IL6 PCSK9
5 extracellular region GO:0005576 9.73 ACE ALB APOA1 APOB APOE CETP
6 platelet alpha granule lumen GO:0031093 9.71 ALB SERPINE1 VWF
7 very-low-density lipoprotein particle GO:0034361 9.65 APOA1 APOB APOE
8 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
9 low-density lipoprotein particle GO:0034362 9.61 APOA1 APOB APOE
10 chylomicron GO:0042627 9.58 APOA1 APOB APOE
11 spherical high-density lipoprotein particle GO:0034366 9.55 APOA1 PON1
12 discoidal high-density lipoprotein particle GO:0034365 9.49 APOA1 APOE
13 high-density lipoprotein particle GO:0034364 9.46 APOA1 APOE CETP PON1
14 intermediate-density lipoprotein particle GO:0034363 9.43 APOA1 APOB APOE
15 extracellular space GO:0005615 9.4 ACE ALB APOA1 APOB APOE CETP
16 extracellular exosome GO:0070062 10.11 ACE ALB APOA1 APOB APOE CETP

Biological processes related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.95 ALB APOA1 APOB APOE IL6 PCSK9
2 receptor-mediated endocytosis GO:0006898 9.92 ALB APOA1 APOB APOE
3 lipid transport GO:0006869 9.9 APOA1 APOB APOE CETP
4 cellular response to lipopolysaccharide GO:0071222 9.89 ICAM1 IL6 SERPINE1 TLR4
5 platelet degranulation GO:0002576 9.88 ALB APOA1 SERPINE1 VWF
6 defense response to Gram-negative bacterium GO:0050829 9.84 IL6 SERPINE1 TLR4
7 retinoid metabolic process GO:0001523 9.8 APOA1 APOB APOE
8 steroid metabolic process GO:0008202 9.8 APOA1 APOB APOE CETP PCSK9
9 cellular protein metabolic process GO:0044267 9.8 ALB APOA1 APOB APOE IL6 PCSK9
10 triglyceride metabolic process GO:0006641 9.78 APOE CETP PCSK9
11 triglyceride homeostasis GO:0070328 9.74 APOA1 APOE CETP
12 cholesterol transport GO:0030301 9.73 APOA1 APOB CETP
13 triglyceride catabolic process GO:0019433 9.72 APOA1 APOB APOE
14 cholesterol efflux GO:0033344 9.7 APOA1 APOB APOE
15 positive regulation of chemokine production GO:0032722 9.69 IL6 TLR4
16 heart contraction GO:0060047 9.69 ACE TNNI3
17 negative regulation of blood coagulation GO:0030195 9.69 APOE SERPINE1
18 reverse cholesterol transport GO:0043691 9.69 APOA1 APOE CETP
19 positive regulation of cholesterol efflux GO:0010875 9.68 APOE PON1
20 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.68 CETP CRP
21 high-density lipoprotein particle assembly GO:0034380 9.68 APOA1 APOE
22 phospholipid efflux GO:0033700 9.68 APOA1 APOE
23 phosphatidylcholine metabolic process GO:0046470 9.67 CETP PON1
24 neutrophil mediated immunity GO:0002446 9.67 ACE IL6
25 low-density lipoprotein particle remodeling GO:0034374 9.67 APOB APOE CETP
26 phospholipid homeostasis GO:0055091 9.66 APOA1 CETP
27 negative regulation of lipid storage GO:0010888 9.66 CRP IL6
28 positive regulation of cholesterol esterification GO:0010873 9.65 APOA1 APOE
29 high-density lipoprotein particle clearance GO:0034384 9.65 APOA1 APOE
30 chylomicron remnant clearance GO:0034382 9.65 APOB APOE
31 neuron projection regeneration GO:0031102 9.64 APOA1 APOE
32 regulation of Cdc42 protein signal transduction GO:0032489 9.64 APOA1 APOE
33 very-low-density lipoprotein particle remodeling GO:0034372 9.63 APOE CETP
34 chylomicron assembly GO:0034378 9.63 APOA1 APOB APOE
35 very-low-density lipoprotein particle clearance GO:0034447 9.62 APOB APOE
36 lipoprotein catabolic process GO:0042159 9.61 APOB APOE
37 chylomicron remodeling GO:0034371 9.61 APOA1 APOB APOE
38 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.58 APOE PCSK9
39 lipoprotein metabolic process GO:0042157 9.56 APOA1 APOB APOE PCSK9
40 cholesterol homeostasis GO:0042632 9.55 APOA1 APOB APOE CETP PCSK9
41 lipoprotein biosynthetic process GO:0042158 9.54 APOA1 APOB APOE
42 high-density lipoprotein particle remodeling GO:0034375 9.26 ALB APOA1 APOE CETP
43 cholesterol metabolic process GO:0008203 9.1 APOA1 APOB APOE CETP PCSK9 PON1
44 lipid metabolic process GO:0006629 10.01 APOA1 APOB APOE CETP PCSK9 PON1

Molecular functions related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.72 ALB APOA1 APOB APOE CETP
2 cholesterol binding GO:0015485 9.58 APOA1 APOE CETP
3 phospholipid binding GO:0005543 9.56 APOA1 APOB APOE PON1
4 phospholipid transporter activity GO:0005548 9.51 APOA1 CETP
5 low-density lipoprotein particle binding GO:0030169 9.49 CRP PCSK9
6 lipoprotein particle binding GO:0071813 9.48 APOA1 APOE
7 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.46 APOA1 APOE
8 lipid transporter activity GO:0005319 9.46 APOA1 APOB APOE CETP
9 very-low-density lipoprotein particle receptor binding GO:0070326 9.43 APOE PCSK9
10 apolipoprotein receptor binding GO:0034190 9.37 APOA1 PCSK9
11 low-density lipoprotein particle receptor binding GO:0050750 9.26 APOB APOE CRP PCSK9
12 cholesterol transporter activity GO:0017127 8.92 APOA1 APOB APOE CETP
Sources

Sources for Coronary Stenosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....